Hylan G-F 20 maintains cartilage integrity and decreases osteophyte formation in osteoarthritis through both anabolic and anti-catabolic mechanisms

Osteoarthritis and Cartilage

Volumn 20, Issue 11, 2012, Pages 1336-1346

  Li, P ^a,b   Raitcheva, D ^a,c   Hawes, M ^a,d   Moran, N ^a   Yu, X ^a   Wang, F ^a   Matthews, G L ^a  

^a GENZYME CORPORATION   (United States)

^b Medtronic Sofamor Danek   (United States)

^c Process Sciences and Production Novartis Biologics   (United States)

^d Charter Preclinical Services   (United States)

Author keywords

Cartilage; Chondroprotection; Hylan G F 20; Osteoarthritis; Rabbit model

Indexed keywords

COLLAGEN TYPE 2; COLLAGENASE 3; GLYCOSAMINOGLYCAN; HYALURONIC ACID; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 16; MESSENGER RNA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STROMELYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CARTILAGE; CATABOLISM; CONTROLLED STUDY; COW; DRUG EFFECT; DRUG MECHANISM; EXPLANT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; NONHUMAN; OSTEOARTHRITIS; OSTEOPHYTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; SYNOVIUM;

AGED; ANIMALS; BIOCOMPATIBLE MATERIALS; CARTILAGE, ARTICULAR; CATTLE; CELLS, CULTURED; CHONDROCYTES; DISEASE MODELS, ANIMAL; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MALE; OSTEOARTHRITIS; OSTEOPHYTE; RABBITS;

EID: 84866440971     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2012.07.004     Document Type: Article

References (49)

1. Balazs E.A., Watson D., Duff I.F., Roseman S. Hyaluronic acid in synovial fluid I. Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis Rheum 1967, 10(4):357-376.
2. Dahl L.B., Dahl I.M., Engstrom-Laurent A., Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis 1985, 44(12):817-822.
3. Balazs E.A., Denlinger J.L. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol 1993, 20(Suppl 39):3-9.
4. Jubb R.W., Piva S., Beinat L., Dacre J., Gishen P. A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract 2003, 57(6):467-474.
5. Wang Y., Hall S., Hanna F., Wluka A.E., Grant G., Marks P., et al. Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculoskelet Disord 2011, 12195.
6. Waddell D.D., Kolomytkin O.V., Dunn S., Marino A.A. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res 2007, 465241-465248.
7. Shimizu M., Higuchi H., Takagishi K., Shinozaki T., Kobayashi T. Clinical and biochemical characteristics after intra-articular injection for the treatment of osteoarthritis of the knee: prospective randomized study of sodium hyaluronate and corticosteroid. J Orthop Sci 2010, 15(1):51-56.
8. ®) on osteoarthritis progression in a rabbit model. Osteoarthritis Cartilage 2003, 11(9):636-643.
9. Marshall K.W., Manolopoulos V., Mancer K., Staples J., Damyanovich A. Amelioration of disease severity by intraarticular hylan therapy in bilateral canine osteoarthritis. J Orthop Res 2000, 18(3):416-425.
10. Schiavinato A., Lini E., Guidolin D., Pezzoli G., Botti P., Martelli M., et al. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs II. Morphological findings. Clin Orthop 1989, 241:286-299.
11. Wenz W., Breusch S.J., Graf J., Stratmann U. Ultrastructural findings after intraarticular application of hyaluronan in a canine model of arthropathy. J Orthop Res 2000, 18(4):604-612.
12. Mihara M., Higo S., Uchiyama Y., Tanabe K., Saito K. Different effects of high molecular weight sodium hyaluronate and NSAID on the progression of the cartilage degeneration in rabbit OA model. Osteoarthritis Cartilage 2007, 15543-15549.
13. Hashizume M., Mihara M. Desirable effect of combination therapy with high molecular weight hyaluronate and NSAIDs on MMP production. Osteoarthritis Cartilage 2009, 17(11):1513-1518.
14. Camplejohn K.L., Allard S.A. Limitations of safranin 'O' staining in proteoglycan-depleted cartilage demonstrated with monoclonal antibodies. Histochemistry 1988, 89(2):185-188.
15. Enobakhare B.O., Bader D.L., Lee D.A. Quantification of sulfated glycosaminoglycans in chondrocyte/alginate cultures, by use of 1,9-dimethylmethylene blue. Anal Biochem 1996, 243(1):189-191.
16. Farndale R.W., Buttle D.J., Barrett A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986, 883(2):173-177.
17. Chin J., Cameron P.M., Rupp E., Schmidt J.A. Identification of a high-affinity receptor for native human interleukin 1 beta and interleukin 1 alpha on normal human lung fibroblasts. J Exp Med 1987, 165(1):70-86.
18. Ham K.D., Loeser R.F., Lindgren B.R., Carlson C.S. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002, 46(7):1956-1964.
19. Bloom K., Harrington D. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol 2004, 121(5):620-630.
20. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408.
21. Davidson R.K., Waters J.G., Kevorkian L., Darrah C., Cooper A., Donell S.T., et al. Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther 2006, 8(4):R124.
22. Kevorkian L., Young D.A., Darrah C., Donell S.T., Shepstone L., Porter S., et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004, 50(1):131-141.
23. Yoshioka M., Coutts R.D., Amiel D., Hacker S.A. Characterization of a model of osteoarthritis in the rabbit knee. Osteoarthritis Cartilage 1996, 4(2):87-98.
24. Westacott C.I., Whicher J.T., Barnes I.C., Thompson D., Swan A.J., Dieppe P.A. Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis 1990, 49(9):676-681.
25. Wobig M., Dickhut A., Maier R., Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998, 20(3):410-423.
26. Wieland H.A., Michaelis M., Kirschbaum B.J., Rudolphi K.A. Osteoarthritis - an untreatable disease?. Nat Rev Drug Discov 2005, 4(4):331-344.
27. Jackson D.W., Simon T.M. Intra-articular distribution and residence time of Hylan A and B: a study in the goat knee. Osteoarthritis Cartilage 2006, 14(12):1248-1257.
28. Greenberg D.D., Stoker A., Kane S., Cockrell M., Cook J.L. Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. Osteoarthritis Cartilage 2006, 14(8):814-822.
29. Karna E., Miltyk W., Surazynski A., Palka J.A. Protective effect of hyaluronic acid on interleukin-1-induced deregulation of beta(1)-integrin and insulin-like growth factor-I receptor signaling and collagen biosynthesis in cultured human chondrocytes. Mol Cell Biochem 2007, 308(1-2):57-64.
30. Kaplan L.D., Lu Y., Snitzer J., Nemke B., Hao Z., Biro S., et al. The effect of early hyaluronic acid delivery on the development of an acute articular cartilage lesion in a sheep model. Am J Sports Med 2009, 37(12):2323-2327.
31. Roth A., Mollenhauer J., Wagner A., Fuhrmann R., Straub A., Venbrocks R.A., et al. Intra-articular injections of high-molecular-weight hyaluronic acid have biphasic effects on joint inflammation and destruction in rat antigen-induced arthritis. Arthritis Res Ther 2005, 7(3):R677-R686.
32. Julovi S.M., Ito H., Hiramitsu T., Yasuda T., Nakamura T. Hyaluronan inhibits IL-1beta-stimulated collagenase production via down-regulation of phosphorylated p38 in SW-1353 human chondrosarcoma cells. Mod Rheumatol 2008, 18(3):263-270.
33. Hsieh Y., Yang S., Lue K., Chu S., Lu K. Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis. J Orthop Res 2008, 26(4):475-484.
34. Wang C.T., Lin Y.T., Chiang B.L., Lin Y.H., Hou S.M. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 2006, 14(12):1237-1247.
35. Huang T.L., Hsu H.C., Yang K.C., Yao C.H., Lin F.H. Effect of different molecular weight hyaluronans on osteoarthritis-related protein production in fibroblast-like synoviocytes from patients with tibia plateau fracture. J Trauma 2010, 68(1):146-152.
36. Echigo R., Mochizuki M., Nishimura R., Sasaki N. Suppressive effect of hyaluronan on chondrocyte apoptosis in experimentally induced acute osteoarthritis in dogs. J Vet Med Sci 2006, 68(8):899-902.
37. Jansen E.J., Emans P.J., Douw C.M., Guldemond N.A., Van Rhijn L.W., Bulstra S.K., et al. One intra-articular injection of hyaluronan prevents cell death and improves cell metabolism in a model of injured articular cartilage in the rabbit. J Orthop Res 2008, 26(5):624-630.
38. Aruffo A., Stamenkovic I., Melnick M., Underhill C.B., Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 61(7):1303-1313.
39. Salter D.M., Godolphin J.L., Gourlay M.S., Lawson M.F., Hughes D.E., Dunne E. Analysis of human articular chondrocyte CD44 isoform expression and function in health and disease. J Pathol 1996, 179396-179402.
40. Davies M.E., Dingle J.T., Pigott R., Power C., Sharma H. Expression of intercellular adhesion molecule 1 (ICAM-1) on human articular cartilage chondrocytes. Connect Tissue Res 1991, 26(3):207-216.
41. McCourt P.A., Ek B., Forsberg N., Gustafson S. Intercellular adhesion molecule-1 is a cell surface receptor for hyaluronan. J Biol Chem 1994, 269(48):30081-30084.
42. Julovi S.M., Yasuda T., Shimizu M., Hiramitsu T., Nakamura T. Inhibition of interleukin-1β-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum 2004, 50(1):516-525.
43. Julovi S.M., Ito H., Nishitani K., Jackson C.J., Nakamura T. Hyaluronan inhibits matrix metalloproteinase-13 in human arthritic chondrocytes via CD44 and P38. J Orthop Res 2011, 29(2):258-264.
44. Brandt K.D. Osteophytes in osteoarthritis. Clinical aspects. Osteoarthritis Cartilage 1999, 7(3):334-335.
45. van Osch G.J., van der Kraan P.M., van Valburg A.A., van den Berg W.B. The relation between cartilage damage and osteophyte size in a murine model for osteoarthritis in the knee. Rheumatol Int 1996, 16(3):115-119.
46. Lanyon P., O'Reilly S., Jones A., Doherty M. Radiographic assessment of symptomatic knee osteoarthritis in the community: definitions and normal joint space. Ann Rheum Dis 1998, 57(10):595-601.
47. Altman R., Brandt K., Hochberg M., Moskowitz R. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilage 1996, 4217-4243.
48. Goldberg V.M., Buckwalter J.A. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage 2005, 13216-13224.
49. Moreland L.W. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanism of action. Arthritis Res Ther 2003, 554-567.